Skip to main content
Erschienen in: Tumor Biology 7/2016

06.01.2016 | Original Article

Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer

verfasst von: Jun Gu, Jie Chen, Jian Feng, Yifei Liu, Qun Xue, Guoxin Mao, Ling Gai, Xiaoning Lu, Rui Zhang, Jialin Cheng, Yanxia Hu, Mengting Shao, Hong Shen, Jianan Huang

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Non-small cell lung cancer (NSCLC) is the major cause of cancer-related lethality among human cancer patients globally, and the poor prognosis of this cancer is mainly explained by metastasis, so it is essential to find out the molecule mechanisms and a novel therapeutic for NSCLC. A disintegrin and metalloprotease with thrombospondin motif 5 (ADAMTS5) belongs to the protease family. It has been reported to participate in tumor migration and invasion. In this study, we showed that the expression of ADAMTS5 was higher in lung cancer tissues by Western blot. The immunohistochemistry analysis was performed in 140 NSCLC cases, and the result indicated that ADAMTS5 was significantly associated with clinical pathologic variables. The Kaplan–Meier curve showed that the high expression of ADAMTS5 was related to poor prognosis of lung cancer patients. Wound healing assays and transwell migration assays revealed that the high expression of ADAMTS5 promoted the migration and invasion of NSCLC. In a word, our findings suggest that ADAMTS5 can regulate the migration and invasion of NSCLC and it may be a useful target of therapy in NSCLC.
Literatur
3.
5.
Zurück zum Zitat Liu SV, Giaccone G. Lung cancer in 2013: refining standard practice and admitting uncertainty. Nat Rev Clin Oncol. 2014;11(2):69–70.CrossRefPubMed Liu SV, Giaccone G. Lung cancer in 2013: refining standard practice and admitting uncertainty. Nat Rev Clin Oncol. 2014;11(2):69–70.CrossRefPubMed
6.
7.
Zurück zum Zitat Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.CrossRefPubMed Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.CrossRefPubMed
8.
Zurück zum Zitat Barney LE et al. A cell-ECM screening method to predict breast cancer metastasis. Integr Biol (Camb). 2015;7(2):198–212.CrossRef Barney LE et al. A cell-ECM screening method to predict breast cancer metastasis. Integr Biol (Camb). 2015;7(2):198–212.CrossRef
9.
Zurück zum Zitat Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010;11(9):633–43.CrossRefPubMedPubMedCentral Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010;11(9):633–43.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sung SY et al. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.CrossRefPubMed Sung SY et al. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.CrossRefPubMed
11.
Zurück zum Zitat Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74.CrossRefPubMed Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74.CrossRefPubMed
13.
Zurück zum Zitat Ohtsuka T et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer. 2006;118(2):263–73.CrossRefPubMed Ohtsuka T et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer. 2006;118(2):263–73.CrossRefPubMed
14.
Zurück zum Zitat Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006;25(1):57–68.CrossRefPubMed Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006;25(1):57–68.CrossRefPubMed
15.
Zurück zum Zitat Shao S et al. ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer. PLoS One. 2014;9(1), e85936.CrossRefPubMedPubMedCentral Shao S et al. ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer. PLoS One. 2014;9(1), e85936.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ishikawa N et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004;10(24):8363–70.CrossRefPubMed Ishikawa N et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004;10(24):8363–70.CrossRefPubMed
17.
18.
Zurück zum Zitat Rocks N et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer. 2006;94(5):724–30.PubMedPubMedCentral Rocks N et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer. 2006;94(5):724–30.PubMedPubMedCentral
19.
Zurück zum Zitat O’Shea C et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105(6):754–61.CrossRefPubMed O’Shea C et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105(6):754–61.CrossRefPubMed
20.
Zurück zum Zitat Kveiborg M et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 2005;65(11):4754–61.CrossRefPubMed Kveiborg M et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 2005;65(11):4754–61.CrossRefPubMed
21.
Zurück zum Zitat Lei Y et al. Interaction of LHBs with C53 promotes hepatocyte mitotic entry: a novel mechanism for HBV-induced hepatocellular carcinoma. Oncol Rep. 2012;27(1):151–9.PubMed Lei Y et al. Interaction of LHBs with C53 promotes hepatocyte mitotic entry: a novel mechanism for HBV-induced hepatocellular carcinoma. Oncol Rep. 2012;27(1):151–9.PubMed
22.
Zurück zum Zitat Nakada M et al. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol. 2005;110(3):239–46.CrossRefPubMed Nakada M et al. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol. 2005;110(3):239–46.CrossRefPubMed
24.
Zurück zum Zitat Wood SL et al. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed Wood SL et al. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed
25.
Zurück zum Zitat Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621–8.CrossRefPubMed Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621–8.CrossRefPubMed
Metadaten
Titel
Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer
verfasst von
Jun Gu
Jie Chen
Jian Feng
Yifei Liu
Qun Xue
Guoxin Mao
Ling Gai
Xiaoning Lu
Rui Zhang
Jialin Cheng
Yanxia Hu
Mengting Shao
Hong Shen
Jianan Huang
Publikationsdatum
06.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4573-x

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.